[Value of mitoxantrone in metastatic hormone-resistant prostate cancer].

Abstract

INTRODUCTION:

The second-line treatment of hormone-resistant metastatic prostate cancer is controversial. This study was designed to evaluate the efficacy and toxicity of mitoxantrone in this clinical situation.

MATERIALS AND METHODS:

The author report a retrospective study of 16 patients with a mean age of 69 years (range: 51-80 years). In each case, the treatment regimen consisted of castration followed by fosfestrol tetrasodium after hormonal escape and second-line treatment with mitoxantrone at a dose of 12 mg/m2 per course (1 to 10 courses) associated with prednisone at a dose of 10 mg/day. The authors evaluated the response to treatment (clinical status and survival) as a function of the following parameters: initial PSA, Gleason score, number of bone metastases, time to hormonal escape, PSA and Karnofsky index on inclusion and total number of courses of mitoxantrone.

RESULT:

Two groups of eight patients were defined as a function of clinical status at the end of each course: group 1 (partial regression and no change) and group 2 (tumour progression). A correlation was demonstrated between the time to hormonal escape and the number of courses and the response to treatment (p = 0.058). The mean survival after introduction of mitoxantrone was 13 months with a significant difference (p = 0.0004) for a cut-off value of 4 courses: 7 months (n < or = 4) and 18 months (n > 4).

CONCLUSION:

Mitoxantrone is a minimally toxic chemotherapeutic agent, which justifies its current indication in hormone-resistant advanced prostate cancer.

• Authors: Alain Khalaf, Christian Pfister, Marie-France Hellot, Frédéric Dunet, Jacques Moussu, Philippe Grise
• Journal: Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie (Prog Urol) Vol. 12 Issue 1 Pg. 37-42 (Feb 2002) ISSN: 1166-7087 [Print] France
• Vernacular Title: Intérêt de la mitoxantrone dans le cancer de prostate métastasé hormono-résistant.
• PMID: 11980013 (Publication Type: English Abstract, Journal Article)

Chemical References

• Androgen Antagonists
• Antineoplastic Agents
• Mitoxantrone

Topics

• Aged
• Aged, 80 and over
• Androgen Antagonists (therapeutic use)
• Antineoplastic Agents (therapeutic use)
• Drug Resistance, Neoplasm
• Humans
• Male
• Middle Aged
• Mitoxantrone (therapeutic use)
• Neoplasm Metastasis
• Prostatic Neoplasms (drug therapy, pathology)
• Retrospective Studies